Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Market Analysis & Valuation

UpdatedJul 14, 2026
DataAggregated Company Financials
Companies7803
  • 7D-0.9%
  • 3M7.2%
  • 1Y19.4%
  • YTD8.4%

In the last week, the market has stayed flat, however the Energy sector stood out, gaining 6.4%. Meanwhile, the market is actually up 19% over the past year. Looking forward, earnings are forecast to grow by 18% annually.

Trending IndustriesOil and GasGoldBiotechSoftwareRenewable Energy

Market Valuation and Performance

Has the U.S. Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Jul 2026US$81.1tUS$24.3tUS$2.5t19.2x32.6x3.3x
Fri, 12 Jun 2026US$78.2tUS$24.3tUS$2.5t18.9x31.8x3.2x
Sun, 10 May 2026US$72.3tUS$24.1tUS$2.4t19.1x29.9x3x
Tue, 07 Apr 2026US$69.2tUS$23.7tUS$2.3t18.7x30x2.9x
Thu, 05 Mar 2026US$71.6tUS$23.7tUS$2.3t19.2x31.2x3x
Sat, 31 Jan 2026US$73.5tUS$23.4tUS$2.3t19.2x31.8x3.1x
Mon, 29 Dec 2025US$72.7tUS$23.2tUS$2.3t19.2x31.8x3.1x
Wed, 26 Nov 2025US$70.2tUS$23.1tUS$2.3t18.6x30.7x3x
Fri, 24 Oct 2025US$70.6tUS$22.8tUS$2.2t18.8x31.8x3.1x
Sun, 21 Sep 2025US$70.5tUS$22.9tUS$2.2t19.2x32.3x3.1x
Tue, 19 Aug 2025US$67.5tUS$23.0tUS$2.2t18.7x31.3x2.9x
Thu, 17 Jul 2025US$65.2tUS$22.5tUS$2.1t18.6x31.1x2.9x
Sat, 14 Jun 2025US$63.0tUS$22.5tUS$2.1t17.7x30x2.8x
Mon, 12 May 2025US$58.8tUS$22.4tUS$2.1t17.5x28.1x2.6x
Wed, 09 Apr 2025US$52.3tUS$21.9tUS$2.1t15.6x25.5x2.4x
Fri, 07 Mar 2025US$60.9tUS$21.9tUS$2.0t17.5x29.8x2.8x
Sun, 02 Feb 2025US$63.9tUS$22.1tUS$2.0t18.6x31.8x2.9x
Tue, 31 Dec 2024US$62.6tUS$22.0tUS$1.9t18.2x32.3x2.8x
Thu, 28 Nov 2024US$63.6tUS$22.0tUS$1.9t19.5x33x2.9x
Sat, 26 Oct 2024US$60.2tUS$21.7tUS$1.9t17.9x32.3x2.8x
Mon, 23 Sep 2024US$59.0tUS$21.5tUS$1.9t18.2x31.7x2.7x
Wed, 21 Aug 2024US$57.9tUS$21.5tUS$1.8t17.8x31.4x2.7x
Fri, 19 Jul 2024US$58.1tUS$21.3tUS$1.8t17.8x31.5x2.7x
Sun, 16 Jun 2024US$56.1tUS$21.3tUS$1.8t16.5x30.6x2.6x
Tue, 14 May 2024US$54.2tUS$21.2tUS$1.8t17.5x29.9x2.6x
Thu, 11 Apr 2024US$54.2tUS$21.1tUS$1.8t17x29.4x2.6x
Sat, 09 Mar 2024US$53.4tUS$21.1tUS$1.8t16.5x29x2.5x
Mon, 05 Feb 2024US$51.6tUS$21.1tUS$1.8t17x29.2x2.5x
Wed, 03 Jan 2024US$49.9tUS$21.0tUS$1.8t16.9x28.4x2.4x
Fri, 01 Dec 2023US$47.5tUS$21.0tUS$1.8t15.9x27.1x2.3x
Sun, 29 Oct 2023US$43.1tUS$21.0tUS$1.7t14.7x24.8x2.1x
Tue, 26 Sep 2023US$45.7tUS$20.9tUS$1.7t15.4x26.6x2.2x
Thu, 24 Aug 2023US$46.7tUS$20.9tUS$1.7t15.7x27.3x2.2x
Sat, 22 Jul 2023US$48.0tUS$21.0tUS$1.7t15.8x28.7x2.3x
Price to Earnings Ratio

28.7x


Total Market Cap: US$48.0tTotal Earnings: US$1.7tTotal Revenue: US$21.0tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Market Price to Earnings3Y Average 30.1x202420252026
Current Market PE
  • Investors are relatively neutral on the American market at the moment, indicating that they expect earnings will grow in line with historical growth rates.
  • The market is trading at a PE ratio close to its 3-year average PE ratio of 30.1x.
Past Earnings Growth
  • The earnings for American listed companies have grown 14% per year over the last three years.
  • Revenues for these companies have grown 5.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Sector Trends

Which sectors have driven the changes within the U.S. Market?

US Market-0.93%
Energy6.40%
Utilities0.87%
Consumer Staples0.77%
Real Estate0.19%
Financials-0.43%
Tech-0.56%
Consumer Discretionary-0.76%
Healthcare-0.85%
Materials-3.06%
Telecom-3.21%
Industrials-3.37%
Sector PE
  • Investors favour the Healthcare sector the most for future growth even though it's trading below its 3-year average PE ratio of 65.5x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 18.2%, which is higher than its past year's earnings growth of 12.6% per year.
  • The Financials sector is the least preferred by investors for future growth, which is trading close to its 3-year average of 17.6x.
Forecasted Growth
  • Analysts are most optimistic on the Telecom sector, expecting annual earnings growth of 23% over the next 5 years.
  • This is better than its past earnings decline of 2.6% per year.
  • In contrast, the Real Estate sector is expected to see its earnings grow by 8.2% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NVDA NVIDIAUS$211.807.6%
+US$360.2b		24.1%PE32.1xTech
META Meta PlatformsUS$661.047.4%
+US$115.4b		-6.9%PE23.8xTelecom
AVGO BroadcomUS$389.114.9%
+US$87.2b		38.5%PE63.1xTech
AAPL AppleUS$314.861.4%
+US$61.7b		50.6%PE37.7xTech
AMD Advanced Micro DevicesUS$548.136.2%
+US$52.2b		252.2%PE181.2xTech
See more

Market Insights

Header cover image
No financial statement shows what a brand is 'worth' despite it being an incredibly valuable asset for some companies. In the volatile world of social media hypes and fads, it's worth understanding what makes a true enduring brand.
Continue reading
Q-Day: The risk the market forgot to reprice

Latest News

SPCX
US$136.08
Space Exploration Technologies
7D
-9.0%
1Y
n/a
IBM
US$217.07
International Business Machines
7D
-29.1%
1Y
-23.2%
ORCL
US$127.94
Oracle
7D
-9.6%
1Y
-45.5%
NVDA
US$211.80
NVIDIA
7D
7.6%
1Y
24.1%
Seeking Alpha • 12h

Nvidia: The Valuation Gap May Collapse With This Q2 Catalyst, Lifting The Stock

Summary Nvidia Corporation remains a compelling investment opportunity, make even more appealing for its massive valuation gap. This valuation gap belies its unmatched revenue growth trajectory, supporting a continued bullish outlook. Risks include potential supply chain constraints and competitive pressures, but NVDA's execution and innovation mitigate these concerns. I maintain a strong conviction in NVDA's long-term upside, supported by secular AI trends resulting in superior growth at the top line. Read the full article on Seeking Alpha
META
US$661.04
Meta Platforms
7D
7.4%
1Y
-6.9%
Seeking Alpha • 19h

Meta's $135 Billion Question: Can AI Compute Turn CapEx Into A New Growth Engine?

Summary My answer to the title: not yet, and maybe never the way bulls hope. Selling compute is unlikely to match the roughly 52% operating margin of Meta’s Family of Apps. Two things flipped it in July: a Bloomberg report on a Meta cloud business, and a paid model API. Suddenly, the capex looked rentable, not dead money. What I need on the 29th of July is proof that Meta Compute actually exists. Named customers would be very welcome. At 20x forward earnings, it's the cheapest of the big four, and 3.56 billion daily users mean Meta wins on distribution even if it never wins the frontier models. Read the full article on Seeking Alpha
GOOGL
US$359.51
Alphabet
7D
-2.0%
1Y
97.5%
AAPL
US$314.86
Apple
7D
1.4%
1Y
50.6%
AMAT
US$595.70
Applied Materials
7D
7.4%
1Y
198.9%
MSFT
US$384.93
Microsoft
7D
-1.0%
1Y
-23.9%
New Narrative • Jul 13

Microsoft (MSFT): The AI Bull Case Everyone Sees, Trading at a Multiple Nobody's Willing to Pay

What Microsoft Actually Does (And Why the Bear Case Misreads It) Most retail investors think of Microsoft as "the Windows and Office company that also does AI now." That framing is about eight years out of date. Microsoft today is a three-headed compounding machine — enterprise productivity software, cloud infrastructure, and, increasingly, the metering layer for the entire AI economy — and the third head is growing fast enough to change how the other two should be valued.
BRK.A
US$737,000.00
Berkshire Hathaway
7D
-2.5%
1Y
4.5%
JNJ
US$253.85
Johnson & Johnson
7D
-5.0%
1Y
63.6%
AVGO
US$389.11
Broadcom
7D
4.9%
1Y
38.5%
LLY
US$1,152.54
Eli Lilly
7D
-6.7%
1Y
49.3%
Narrative Update • Jul 10

LLY: GLP-1 Franchise And Retatrutide Data Will Support Balanced Future Outlook

Analysts have nudged their price targets on Eli Lilly higher, with fair value estimates moving from about $1,218.72 to roughly $1,243.43 as they point to resilient GLP-1 obesity and diabetes franchises, along with supportive recent data and previews around Zepbound, Mounjaro, Foundayo and retatrutide. Analyst Commentary Recent research updates on Eli Lilly show a cluster of higher price targets around the GLP-1 obesity and diabetes portfolio, with Zepbound, Mounjaro, Foundayo and retatrutide at the center of the discussion.
AMD
US$548.13
Advanced Micro Devices
7D
6.2%
1Y
252.2%
BABA
US$112.32
Alibaba Group Holding
7D
14.4%
1Y
-4.0%
MU
US$983.12
Micron Technology
7D
4.8%
1Y
718.5%